Specialty Pharmacy-Times: Advocates Disagree on the Impact of DIR Fees on Part D Drugs

Specialty Pharmacy-Times: Advocates Disagree on the Impact of DIR Fees on Part D Drugs

“Without DIR, Part D premiums and program costs would be much higher,” Mark Merritt, president and CEO of PCMA.